Oliver Wright

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

E. Kimby, A. Pettitt, A. Schuh, 2015, The Lancet.

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.

Z. Aziz, J. Strausz, M. Guckert, 2009, The Lancet. Oncology.

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

A. Makhson, P. Dubé, P. Hesketh, 2012, Supportive Care in Cancer.

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

I. Flinn, B. Afanasyev, K. Kuliczkowski, 2016, American journal of hematology.

Assessment of the effect of ofatumumab on cardiac repolarization

C. Hottenstein, G. Chan, Eric Lewis, 2015, Journal of clinical pharmacology.

Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)

Z. Aziz, J. Strausz, M. Guckert, 2008 .

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

I. Flinn, B. Afanasyev, K. Kuliczkowski, 2016, American journal of hematology.